News | November 10, 2021
Pulmatrix resolves dispute with Cipla
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The company has operations in North America, Asia, and Europe,
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Clear aligners are a series of tight-fitting custom-made mouthpieces or orthodontic systems that are useful in correcting misaligned or crooked teeth
The NFI is published to promote the rational use of medicines in the country.
Subscribe To Our Newsletter & Stay Updated
